


Phase III COMBI-AD

COMBI-AD

Image



2017年6月30日

2018年4月30日

2019年11月8日

RFS, Relapse Free Survival; OS: Overall Survival; DMFS: Distant Metastasis Free Survival:

FFR: Freedom From Relapse,

Long, GV. et al. N. Engl. J. Med. 2017; 377:19: 1813-1823. 20180231
4
10

CTD2.7.6.4.1.1.

20180229 Hauschild, A. et al. J. Clin. Oncol. 2018; 36:35: 3441-3449
4
17

Dummer, R. et al. N. Engl. J. Med. 2020; 383:12: 1139-1148
3

BRAF V600E/K AJCC 7
870

BRAF V600E/K AJCC 7 A 1mm B C
870

RFS

OS

RFS

Kaplan-Meier log-rank Pike
95%CI A mixed Weibull cure-ratemode

OS


Kaplan-Meier log-rank

Hauschild, A. et al. J. Clin. Oncol. 2018; 36:35: 3441-3449
4
17

Dummer, R. et al. N. Engl. J. Med. 2020; 383:12: 1139-1148
3

RFS

Image



2019年11月8日

Dummer, R. et al. N. Engl. J. Med. 2020; 383(12): 1139-1148

2019年11月8日

- 398/435 (92%) vs 272/432 (63%)
- 244 (56%) vs 170 (39%)
- 155 (36%) vs 85 (20%)
- 52 (12%) vs 50 (12%)
- 155 (36%) vs 1% (0.2%)
- 67 (15%) vs 13 (3%)
- 114 (26%) vs 1% (0.2%)
- 38 (9%) vs 16 (4%)

2019年11月8日

Dummer, R. et al. N. Engl. J. Med. 2020; 383(12): 1139-1148

Long, GV. et al. N. Engl. J. Med. 2017; 377(19): 1813-1823

4
10
F2301 COMBI-AD 20180229

Source URL: https://www.pro.novartis.com/jp-ja/products/tafmek/mel/clinical_01